About: Tocilizumab for severe COVID-19: a systematic review and meta-analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Tocilizumab for severe COVID-19: a systematic review and meta-analysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Tocilizumab for severe COVID-19: a systematic review and meta-analysis
Creator	Hsueh, Po-Ren Lai, Chih-Cheng Chang, Shen-Peng Huang, Hui-Ting Lan, Shao-Huan Lu, Li-Chin
source	Elsevier; Medline; PMC
abstract	This systemic review and meta-analysis aimed to assess the efficacy of tocilizumab for the treatment of severe coronavirus disease-2019 (COVID-19). Candidate studies up to May 24, 2020 were identified from PubMed, Cochrane Library, Embase, MedRxiv, and BioRxiv. Treatment outcomes included mortality, risk of intensive care unit (ICU) admission, and the requirement of mechanical ventilation (MV). A total of 7 retrospective studies involving 593 adult patients with severe COVID-19, including 241 in the tocilizumab group and 352 in the control group were enrolled. All-cause mortality of severe COVID-19 patients among the tocilizumab group was 16.2% (39/241), which was lower than that in the control group (24.1%, 85/352). However, the difference did not reach statistical significance (risk ratio [RR], 0.61; 95% confidence interval [CI], 0.31-1.22, I(2) = 68%). In addition, the risk of ICU admission was similar between the tocilizumab and control groups (35.0% vs. 15.8%, RR, 1.51; 95% CI, 0.33-6.78, I(2) = 86%). The requirement of MV was similar between the tocilizumab and control groups (32.4% vs. 28.6%, RR, 0.72; 95% CI, 0.05-10.96, I(2) = 91%). However, these nonsignificant differences between the tocilizumab and control groups may have been the result of the baseline characteristics of the tocilizumab group, which were more severe than those of the control group. Based on low-quality evidence, there is no conclusive evidence that tocilizumab would provide any additional benefit to patients with severe COVID-19. Therefore, further recommendation of tocilizumab for COVID-19 cases should be halted until high-quality evidence from randomized controlled trials is made available.
has issue date	2020-07-23(xsd:dateTime)
bibo:doi	10.1016/j.ijantimicag.2020.106103
bibo:pmid	32712333
has license	no-cc
sha1sum (hex)	b79e74659bf66617a65515954542d6f2b3addbb6
schema:url	https://doi.org/10.1016/j.ijantimicag.2020.106103
resource representing a document's title	Tocilizumab for severe COVID-19: a systematic review and meta-analysis
has PubMed Central identifier	PMC7377685
has PubMed identifier	32712333
schema:publication	Int J Antimicrob Agents
resource representing a document's body	covid:b79e74659bf66617a65515954542d6f2b3addbb6#body_text
is schema:about of	named entity 'systematic review' named entity 'meta-analysis' named entity 'ICU' covid:arg/b79e74659bf66617a65515954542d6f2b3addbb6 named entity 'tocilizumab' named entity 'tocilizumab' named entity 'control groups' named entity '95% CI' named entity 'tocilizumab' named entity 'tocilizumab' named entity 'control groups' named entity 'COVID-19' named entity 'meta-analysis' named entity 'Tocilizumab' named entity 'COVID-19' named entity 'statistical significance' named entity 'COVID' named entity 'tocilizumab' named entity 'triglycerides' named entity 'CRS' named entity 'MedRxiv' named entity 'pneumonia' named entity 'mortality rate' named entity 'significant difference' named entity 'tocilizumab' named entity 'mortality rate' named entity '19, 20' named entity 'tocilizumab' named entity 'tocilizumab' named entity 'alanine aminotransferase' named entity 'kevzara' named entity 'mortality rates' named entity 'France' named entity 'COVID' named entity 'randomized trials' named entity 'tocilizumab' named entity 'Cochrane Library' named entity 'AST' named entity 'COVID-19' named entity 'meta-analysis' named entity 'directly related' named entity 'cytokine release syndrome' named entity 'IL-6' named entity 'open-label' named entity 'Italy' named entity 'adverse event' named entity 'CRS' named entity 'COVID' named entity 'control group' named entity 'COVID' named entity 'tocilizumab' named entity 'tocilizumab' named entity 'multivariate analysis' named entity 'ICU' named entity 'infection' named entity '95% CI' named entity 'septic shock' named entity 'tocilizumab' named entity 'cytokine storm' named entity 'COVID-19' named entity 'COVID' named entity 'tocilizumab' named entity 'COVID' named entity 'randomized controlled trials' named entity 'SARS-CoV-2' named entity 'retrospective studies' named entity 'Coronavirus disease' named entity 'tocilizumab' named entity 'aspartate aminotransferase' named entity 'subcutaneous injection' named entity 'meta-analysis' named entity 'interleukin-6' named entity 'tocilizumab' named entity 'meta-analysis' named entity 'Heterogeneity' named entity 'IL-6'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software